Cyteir Therapeutics, Inc. Common Stock
CYT
CYT was delisted on the 15th of March, 2024.
0 hedge funds and large institutions have $0 invested in Cyteir Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 4 closing their positions.
100% less funds holding
Funds holding: 4 → 0 (-4)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $11.2M → $0 (-$11.2M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$11M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$77K |
| 3 |
BFO
Boston Family Office
Boston,
Massachusetts
|
-$73K |
| 4 |
LC
Lindbrook Capital
Calabasas,
California
|
-$6.04K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
1
BML Capital Management
Zionsville,
Indiana
| – | -$11M | -3,654,053 | Closed |
|
|
2
Acadian Asset Management
Boston,
Massachusetts
| – | -$77K | -26,319 | Closed |
|
|
BFO
3
Boston Family Office
Boston,
Massachusetts
| – | -$73K | -24,197 | Closed |
|
|
LC
4
Lindbrook Capital
Calabasas,
California
| – | -$6.04K | -2,006 | Closed |
|
CYT Hedge Fund Activity: Q2 2024 in Review
0 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q2 2024, worth a combined $0 — down 100% from $11.2M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CYT and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BML Capital Management, exiting entirely with an estimated $11M sold.
- 0 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q2 2024, down from 4 in Q1 2024.
- Funds reported $0 of Cyteir Therapeutics, Inc. Common Stock stock for Q2 2024, down 100% quarter-over-quarter.
- 0 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q2 2024 and 4 closed out, a net change of -4 holders.
- The largest Cyteir Therapeutics, Inc. Common Stock seller in Q2 2024 was BML Capital Management, an estimated $11M sold.
Based on aggregated 13F filings for Q2 2024.